Rita Lawlor

Rita Lawlor

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2016 in Nature
Verified
Journal Article
Closed access
PDF file
PBPeter Bailey
Peter Bailey
DCDavid K. Chang
David K. Chang
Katia NonesKatia Nones
Katia Nones
AJAmber L. Johns
Amber L. Johns
APAnn-Marie Patch
Ann-Marie Patch
SGSean M. Grimmond
Sean M. Grimmond

25 February 2015 in Nature
Verified
Journal Article
Closed access
PDF file
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
Nic WaddellNic Waddell
Nic Waddell
MPMarina Pajic
Marina Pajic
APAnn-Marie Patch
Ann-Marie Patch
DCDavid K Chang
David K Chang
SGSean M. Grimmond
Sean M. Grimmond

24 October 2012 in Nature
Verified
Journal Article
Closed access
PDF file
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
ABAndrew V. Biankin
Andrew V. Biankin
Nic WaddellNic Waddell
Nic Waddell
KKKarin Kassahn
Karin Kassahn
MGMarie-Claude Gingras
Marie-Claude Gingras
SGSean M. Grimmond
Sean M. Grimmond

15 February 2017 in Nature
Verified
Journal Article
Closed access
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
ASAldo Scarpa
Aldo Scarpa
DCDavid K. Chang
David K. Chang
Katia NonesKatia Nones
Katia Nones
VCVincenzo Corbo
Vincenzo Corbo
SGSean M. Grimmond
Sean M. Grimmond

3 November 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
YJYuchen Jiao
Yuchen Jiao
TPTimothy M Pawlik
Timothy M Pawlik
RARobert A Anders
Robert A Anders
FSFlorin M Selaru
Florin M Selaru
MSMirte M Streppel
Mirte M Streppel
LWLaura D Wood
Laura D Wood

1 May 2018 in Journal of Hepatology
Verified
Journal Article
Open access
CWChristopher Paul Wardell
Christopher Paul Wardell
MFMasashi Fujita
Masashi Fujita
TYToru Yamada
Toru Yamada
Michele SimboloMichele Simbolo
Michele Simbolo
Matteo FassanMatteo Fassan
Matteo Fassan
HNHidewaki Nakagawa
Hidewaki Nakagawa
Biliary tract cancers (BTCs) are clinically and pathologically heterogeneous and respond poorly to treatment. Genomic profiling can offer a clearer understanding of their carcinogenesis, classification and treatment strategy. We performed large-scale genome sequencing analyses on BTCs to investigate their somatic and germline driver events and characterize their genomic landscape. We analyzed 412 BTC samples from Japanese and Italian populations, 107 by whole-exome sequencing (WES), 39 by whole-genome sequencing (WGS), and a further 266 samples by targeted sequencing. The subtypes were 136 intrahepatic cholangiocarcinomas (ICCs), 101 distal cholangiocarcinomas (DCCs), 109 peri-hilar type cholangiocarcinomas (PHCs), and 66 gallbladder or cystic duct cancers (GBCs/CDCs). We identified somatic alterations and searched for driver genes in BTCs, finding pathogenic germline variants of cancer-predisposing genes. We predicted cell-of-origin for BTCs by combining somatic mutation patterns and epigenetic features. We identified 32 significantly and commonly mutated genes including TP53, KRAS, SMAD4, NF1, ARID1A, PBRM1, and ATR, some of which negatively affected patient prognosis. A novel deletion of MUC17 at 7q22.1 affected patient prognosis. Cell-of-origin predictions using WGS and epigenetic features suggest hepatocyte-origin of hepatitis-related ICCs. Deleterious germline mutations of cancer-predisposing genes such as BRCA1, BRCA2, RAD51D, MLH1, or MSH2 were detected in 11% (16/146) of BTC patients. BTCs have distinct genetic features including somatic events and germline predisposition. These findings could be useful to establish treatment and diagnostic strategies for BTCs based on genetic information. We here analyzed genomic features of 412 BTC samples from Japanese and Italian populations. A total of 32 significantly and commonly mutated genes were identified, some of which negatively affected patient prognosis, including a novel deletion of MUC17 at 7q22.1. Cell-of-origin predictions using WGS and epigenetic features suggest hepatocyte-origin of hepatitis-related ICCs. Deleterious germline mutations of cancer-predisposing genes were detected in 11% of patients with BTC. BTCs have distinct genetic features including somatic events and germline predisposition.